Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
AURKA
REST API REST API
Homo sapiens
AURKA is differentially expressed in 350 experiments: 129 organism parts: bone marrow, blood, ... (127 more);, 237 disease states: normal, control, ... (235 more);, 114 cell types 335 cell lines 44 compound treatments and 78 other conditions.
Synonyms ARK1, STK15, BTAK, AurA, STK7, STK6
Orthologs Aurka (Mus musculus)   IPL1 (Saccharomyces cerevisiae)   AURKA (Gallus gallus)   F7A0P0_CIOIN (Ciona intestinalis)   Aurka (Rattus norvegicus)   AURKA_BOVIN (Bos taurus)   aurka (Danio rerio)   aur (Drosophila melanogaster)   ial (Drosophila melanogaster)   aurka (Xenopus laevis)   (Compare orthologs)
Gene Ontology Term protein binding, mitotic cell cycle, protein tyrosine kinase activity, ATP binding, centrosome, spindle, nucleotide binding, kinase activity, protein serine/threonine kinase activity, protein kinase activity, ubiquitin protein ligase binding, response to estradiol stimulus, protein phosphorylation
InterPro Term Prot_kinase_cat_dom, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession Q5QPD4, Q5QPD1, Q5QPD2, A3KFJ0, A3KFJ2, A3KFJ1, O14965
Gene-Disease Assocation COLORECTAL CANCER; CRC
Search EB-eye ENSG00000087586
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-MEXP-433, E-GEOD-3526, ... (35 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (44 experiments)

Factor Value U/D Experiments
BT20
2
E-MTAB-37, E-MTAB-62
T84
2
E-GEOD-1474, E-MTAB-37
MCF-7
1
2
E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
SW480
1
2
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
CMA-02
1
E-MTAB-62
HPAFII
1
E-MTAB-37
329 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-MEXP-66, ... (48 experiments)

Factor Value U/D Experiments
CD8+ T cell
1
3
E-AFMX-5, E-MTAB-25, E-GEOD-19069, E-TABM-145
macrophage
2
E-GEOD-8286, E-GEOD-5099
1
2
E-TABM-130, E-TABM-145
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
108 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-1577, E-TABM-15, ... (75 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-GEOD-2514, E-MTAB-62, E-MEXP-231, E-MTAB-37
cervical carcinoma
3
E-MTAB-62, E-MEXP-1331, E-MTAB-37
prostate carcinoma
3
E-GEOD-96, E-MEXP-2034, E-MTAB-62
benign prostatic hyperplasia
2
E-MEXP-2034, E-MEXP-1243
malignant melanoma
2
E-GEOD-3189, E-MTAB-62
neuroblastoma
2
E-MTAB-62, E-MTAB-37
231 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-1417, E-TABM-782, E-GEOD-5824, ... (30 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-GEOD-3720
PGE2
1
E-MEXP-1230
Ethanol
1
E-MEXP-2417
unknown
1
E-GEOD-7307
HMB-PP (phosphoantigen)
1
E-MEXP-1601
bacterial endotoxin
1
E-GEOD-3284
38 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
GTE6
1
1
E-GEOD-21521
LT6
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (12 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-MEXP-958, ... (6 experiments)

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-MTAB-69, E-TABM-147, ... (9 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-1643

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-GEOD-1923, E-TABM-1029, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-MEXP-2657, E-GEOD-10315, E-TABM-440, E-GEOD-837, ... (18 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-2748

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, ... (30 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-6802 ... (5 experiments)

Injury
studied in E-GEOD-19743, E-GEOD-5372

Irradiate
studied in E-GEOD-1977, E-TABM-321

Karyotype
studied in E-GEOD-7214, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-19703, E-GEOD-22152, E-GEOD-22309, E-GEOD-21750, ... (9 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-20037 ... (5 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, ... (7 experiments)

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400 ... (5 experiments)

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19743, E-GEOD-19069, E-GEOD-7307, E-GEOD-16363, E-GEOD-1295 ... (5 experiments)

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-MEXP-973, E-GEOD-19246, E-GEOD-15799, E-GEOD-12198

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-TABM-43, E-GEOD-6532, ... (7 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.374 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM